1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

NeuClone’s Trastuzumab Trial Succeeds

Reports Successful Phase I Trial For NeuCeptin Trastuzumab Biosimilar

 
• By Akriti Seth

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

Compass_Success
NeuClone and partner Serum Institute of India have reported success in a phase I trial for trastuzumab • Source: Shutterstock

NeuClone Pharmaceuticals has announced that its NeuCeptin (trastuzumab) proposed biosimilar to Herceptin has successfully met all of its primary and secondary endpoints in a Phase I clinical trial. NeuCeptin is “one of several biosimilars developed in partnership between NeuClone and the Serum Institute of India.”

Highlighting the “significant milestone” for the company, NeuClone’s CEO and founder Noelle Sunstrom said the positive results from the NeuCeptin trial “reflect our dedication to provide

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.